Prelude Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Prelude Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$30.7K	–	1490
2026 Q1	$30.7K	Hold	10,000	–	–	﹤0.01%	1150
2025 Q4	$40.9K	Buy	+10,000	New	+$49.5K	﹤0.01%	1246
2024 Q3	–	Sell	-15,794	Closed	-$118K	–	1505
2024 Q2	$118K	Buy	+15,794	New	+$138K	0.01%	1083
2024 Q1	–	Sell	-19,733	Closed	-$195K	–	1503
2023 Q4	$195K	Sell	19,733 -23,226	-54%	-$166K	0.01%	949
2023 Q3	$329K	Buy	42,959 +6,573	+18%	+$65.6K	0.02%	628
2023 Q2	$272K	Buy	+36,386	New	+$255K	0.02%	691
2022 Q3	–	Sell	-18,243	Closed	-$148K	–	1865
2022 Q2	$148K	Buy	+18,243	New	+$122K	﹤0.01%	1355

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Prelude Capital Management's RXRX Position: Q2 2026 in Review

Prelude Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 10,000 shares — an estimated $30.7K sold.

Prelude Capital Management first reported a position in RXRX in Q2 2022 and held it in 7 quarters. The position peaked at $329K in Q3 2023. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Prelude Capital Management reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 10,000 Recursion Pharmaceuticals shares in Q2 2026, an estimated $30.7K.
Prelude Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2022 and held it in 7 quarters.
Prelude Capital Management's Recursion Pharmaceuticals position peaked at $329K in Q3 2023.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.